adMare BioInnovations, Canada's global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (Nasdaq: ABCL). Abdera is a precision oncology company developing novel next-generation targeted alpha therapies (TATs) for patients with relapsed, refractory and metastatic cancers.
Read MoreThe Fonds de solidarité FTQ ( "Fonds") is renewing its partnership with life sciences venture capital firm Forbion by investing €15 million (C$23 million) in Forbion Capital Fund V.
Read MoreadMare BioInnovations, Canada's global life sciences venture, is proud to announce the start-ups selected to join its new acceleration program for Quebec emerging companies.
Read MoreAifred Health, a Montreal-based digital healthcare company, today announced the closing of a $4 million seed financing.
Read MoreExCellThera Inc., a company focusing on cellular and molecular medicine at the advanced clinical stage, will receive a repayable contribution of up to $4 million from Canada Economic Development for Quebec Regions (CED) as part of its launch of commercial production activities.
Read MoreRoche partners with AI leaders Amii, Mila and the Vector Institute to drive digital transformation in health
Read MoreHealth Canada today granted authorization, under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, for the use of bamlanivimab (LY-CoV-555) as a treatment of adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who weigh at least 40 kg and are at high risk of progressing to severe COVID-19 illness and/or hospitalization, Eli Lilly and Company (NYSE: LLY) announced.
Read MoreTVM Capital Life Science, one of the leading life sciences venture capital firms in North America and Europe, today announced the final closing of its latest fund, TVM Life Science Innovation II (TVM LSI II).
Read MoreenGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EG-70, a first-in-class non-viral gene therapy for the expression of innate and adaptive immune system activators circumscribed to the bladder. Under this IND, enGene intends to initiate its Phase 1/2, multi-center study in patients with Bacille Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) in early 2021.
Read MoreEli Lilly and Company and Incyte shared additional data that showed baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir.
Read MoreNovartis Pharmaceuticals Canada Inc. announced today the launch of the Novartis Canada Biome, an innovative hub that will bring together and empower emerging tech companies and people who are passionate about disrupting healthcare through data and digital technologies.
Read MoreGénome Québec, in partnership with the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, Université de Montréal, Mila – Quebec Artificial Intelligence Institute and McMaster University, is proud to announce funding for a new research project intended to accelerate the discovery of antiviral COVID-19 medications.
Read MoreExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA) for ExCellThera’s most advanced technology, ECT-001 Cell Therapy.
Read MoreNovartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Luxturna® (voretigene neparvovec), a one-time gene therapy for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. The presence of biallelic RPE65 mutations should be confirmed by an accredited laboratory using validated assay methods.
Read MoreVerzenio in combination with endocrine therapy is the only CDK4 & 6 inhibitor to demonstrate a statistically significant improvement in invasive disease-free survival (IDFS) in early breast cancer
Read MoreIMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today provides updates on its vaccine candidate, DPX-COVID-19, for the prevention of infection caused by the novel coronavirus SARS-COV-2.
Read MoreThe recent pandemic has highlighted the importance of staying healthy so that you can better fight an infection or disease, if necessary. A Concordia University researcher has discovered 15 new plant extracts that help fight, not against infection, but against aging.
Read MoreDomain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, neurology and rare diseases, announces today the signing of a collaboration agreement with Pfizer Inc.
Read MoreThe Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) are pleased to announce they have formed a new collaboration, “The CPDC-adMare Radiopharmaceutical Initiative (CARI)” to bring their respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain a considerable global competitive advantage: radiopharmaceuticals.
Read MoreTwelve years ago some of the biggest names in pharmaceuticals abandoned a class of weight-loss drugs they had thought would deliver blockbuster sales. The drugs worked – but also caused psychiatric disorders in many patients, and regulators rejected them.
Read More
